Literature DB >> 1384695

Circular dichroism studies suggest that TAR RNA changes conformation upon specific binding of arginine or guanidine.

R Tan1, A D Frankel.   

Abstract

Short basic peptides from the HIV Tat protein bind specifically to a bulge region in TAR RNA, with a single arginine residue providing the only sequence-specific contact. The free amino acid arginine also binds specifically to TAR. Previous circular dichroism (CD) experiments suggested that peptide binding induces a conformational change in TAR. Here we confirm this observation using single arginine-containing peptides and show that arginine or guanidine binding also induces a conformational change in TAR. A peptide containing a single arginine within a stretch of histidines (CYHHHRHHHHHA) shows pH-dependent binding and a corresponding change in TAR conformation, as detected by a decrease in the CD signal at 265 nm. Arginine and guanidine, which bind to TAR with apparent Kd's of approximately 1.5 mM, induce similar CD changes. In contrast, lysine, which does not bind specifically to TAR, has no effect. Mutants of TAR that abolish specific binding (a U-->C substitution in the three-nucleotide bulge, a deletion of the bulge, or an A-U to U-A base pair change above the bulge) show no change in the CD signal upon binding of peptides, arginine, or guanidine. The results suggest that binding of a single guanidinium group to a specific site in TAR induces a change in RNA conformation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384695     DOI: 10.1021/bi00157a016

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  21 in total

1.  Interactions of protein side chains with RNA defined with REDOR solid state NMR.

Authors:  Wei Huang; Gabriele Varani; Gary P Drobny
Journal:  J Biomol NMR       Date:  2011-09-25       Impact factor: 2.835

2.  A quantitative description of the binding states and in vitro function of antitermination protein N of bacteriophage lambda.

Authors:  Clarke R Conant; Marc R Van Gilst; Stephen E Weitzel; William A Rees; Peter H von Hippel
Journal:  J Mol Biol       Date:  2005-04-01       Impact factor: 5.469

Review 3.  Peptide models of the Tat-TAR protein-RNA interaction.

Authors:  A D Frankel
Journal:  Protein Sci       Date:  1992-12       Impact factor: 6.725

4.  Role of RNA structure in arginine recognition of TAR RNA.

Authors:  J D Puglisi; L Chen; A D Frankel; J R Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

5.  MBNL1-RNA recognition: contributions of MBNL1 sequence and RNA conformation.

Authors:  Yuan Fu; Sreenivasa Rao Ramisetty; Nejmun Hussain; Anne M Baranger
Journal:  Chembiochem       Date:  2011-11-22       Impact factor: 3.164

6.  Structural variety of arginine-rich RNA-binding peptides.

Authors:  R Tan; A D Frankel
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-06       Impact factor: 11.205

7.  Design and synthesis of RNA miniduplexes via a synthetic linker approach. 2. Generation of covalently closed, double-stranded cyclic HIV-1 TAR RNA analogs with high Tat-binding affinity.

Authors:  M Y X Ma; K McCallum; S C Climie; R Kuperman; W C Lin; M Sumner-Smith; R W Barnett
Journal:  Nucleic Acids Res       Date:  1993-06-11       Impact factor: 16.971

8.  Duck hepatitis B virus polymerase acts as a suppressor of core protein translation.

Authors:  A Y Howe; D L Tyrrell
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

9.  The bend in RNA created by the trans-activation response element bulge of human immunodeficiency virus is straightened by arginine and by Tat-derived peptide.

Authors:  M Zacharias; P J Hagerman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

10.  Electrostatic interactions modulate the RNA-binding and transactivation specificities of the human immunodeficiency virus and simian immunodeficiency virus Tat proteins.

Authors:  J Tao; A D Frankel
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.